National Pension Service Purchases 33,152 Shares of Illumina, Inc. (NASDAQ:ILMN)

National Pension Service lifted its position in Illumina, Inc. (NASDAQ:ILMNFree Report) by 12.4% in the third quarter, Holdings Channel.com reports. The firm owned 300,661 shares of the life sciences company’s stock after purchasing an additional 33,152 shares during the quarter. National Pension Service’s holdings in Illumina were worth $39,209,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ILMN. Vanguard Group Inc. lifted its stake in Illumina by 0.4% in the first quarter. Vanguard Group Inc. now owns 18,245,041 shares of the life sciences company’s stock worth $2,505,409,000 after purchasing an additional 66,528 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Illumina by 7.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company’s stock valued at $317,267,000 after acquiring an additional 204,043 shares during the period. Capital World Investors grew its position in Illumina by 41.1% during the 1st quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock worth $378,111,000 after acquiring an additional 801,814 shares during the last quarter. Primecap Management Co. CA increased its stake in Illumina by 462.5% in the 2nd quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock worth $253,514,000 after purchasing an additional 1,997,010 shares during the period. Finally, GUARDCAP ASSET MANAGEMENT Ltd lifted its position in Illumina by 1.1% in the first quarter. GUARDCAP ASSET MANAGEMENT Ltd now owns 2,068,869 shares of the life sciences company’s stock valued at $284,097,000 after purchasing an additional 22,067 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Price Performance

NASDAQ ILMN opened at $151.83 on Thursday. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $156.66. The company has a debt-to-equity ratio of 1.04, a current ratio of 1.11 and a quick ratio of 0.86. The stock’s fifty day moving average price is $137.27 and its 200-day moving average price is $123.12.

Illumina (NASDAQ:ILMNGet Free Report) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 6.36%. Illumina’s revenue was down 3.5% compared to the same quarter last year. During the same period last year, the business earned $0.33 EPS. On average, sell-side analysts expect that Illumina, Inc. will post 3.62 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ILMN has been the topic of several analyst reports. HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a research note on Thursday, October 17th. TD Cowen upped their price objective on shares of Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a research note on Tuesday. Leerink Partners raised their target price on Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Scotiabank lowered their price target on Illumina from $176.00 to $164.00 and set a “sector outperform” rating for the company in a research report on Thursday, August 15th. Finally, Piper Sandler cut their price objective on Illumina from $200.00 to $195.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Illumina has a consensus rating of “Moderate Buy” and an average target price of $162.18.

View Our Latest Stock Report on ILMN

About Illumina

(Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Further Reading

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNFree Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.